Village Farms International Third Quarter 2026 Earnings Call - VILLAGE FARMS INTERNATIONAL INC

Financial Performance:

• Consolidated net sales reached $66.9 million, up 5% sequentially and flat year-over-year, driven by a record $55 million in cannabis revenue.
• Net income was $10 million ($0.08 per share), down slightly from $10.8 million in Q3 2025 but up $7.2 million from Q2 2026.
• Adjusted EBITDA improved 18% sequentially to $18.2 million (27% of sales); year-to-date adjusted EBITDA rose 18% to $43.5 million.
• Operating cash flow was $9.5 million; the company ended the quarter with approximately $80 million in cash, up $6.3 million sequentially.
• Long-term debt stood at roughly $39 million with a 5.7% weighted average rate; the $10 million revolver remains undrawn, resulting in a net cash position of $41 million.
• Cannabis segment gross margin was 48% (down from 55% YoY) due to softer trim prices and a shift to bulk flower, while the "Other" segment (clean energy/produce) posted $11.9 million in sales.
• Canadian excise taxes totaled $16.5 million in Q3, representing 39% of gross branded sales.

Guidance and Future Outlook:

• Q4 is expected to face seasonality headwinds: produce sales to Verdexa Holdings typically drop ~60% in Q4, and international medical orders often slow during the European holiday period.
• Delta II expansion is on track for completion in Q1 2027, expected to reach a 40-metric ton annual run rate by mid-2027 to support organic growth through 2028.
• Management exercised an option to convert 25% of the Delta 1 greenhouse to cannabis production, potentially adding 50-60 metric tons of capacity by 2028 if executed.
• Long-term goal involves evolving from a cultivation-focused company to one owning the full value chain, including intellectual property, novel products, and botanical drugs.
• International exports are projected to grow significantly as supply constraints ease with new capacity, particularly for EU GMP-compliant product.
• Canada market growth is expected to be in the mid-single digits, with a strategic focus on profitable market share and defending against competitors exiting the sector.

Business Segments and Product Lines:

• International: Exports grew 75% YoY to $20.8 million; demand for EU GMP-compliant biomass outpaces current supply, with pricing remaining resilient.
• Canada (Domestic): Branded sales reached $25.3 million (+6% ASP YoY) while non-branded sales fell to $3.3 million due to a ~75% YoY drop in spot trim pricing; company holds top 5 market share nationally.
• Netherlands: Sales were $2.8 million, impacted by propagation ramp-up at the Cronogen facility, which is now fully planted and expected to drive growth in Q4 and 2027.
• U.S. (Balanced Health Botanicals): Generated $2.8 million in sales, facing headwinds from unregulated hemp products; actively pursuing federal CBD/Medicare pathways.
• Texas: Announced plans to operationalize a 30-acre, 1.3-million-square-foot Monahans greenhouse for cannabis production, targeting a 12-month timeline to launch pending regulatory reform.

Market and Competitive Landscape:

• EU Market: Regulatory tightening in Germany and the UK is curbing "greenwashing" (conversion of non-GMP flower), favoring at-source EU GMP producers; Village Farms possesses the world's largest single-site EU GMP facility.
• Canada: Competitive dynamics improving as rivals de-emphasize branded sales or exit dry flower; government is cracking down on illicit markets and moving toward a single federal excise stamp.
• U.S. Market: Recent midterm elections in Texas, Ohio, Iowa, and Wisconsin suggest a favorable shift toward cannabis reform; Texas House flipped Democratic, increasing likelihood of medical program expansion.
• Netherlands: Government monitoring reports indicate positive outcomes for the pilot program; however, a reduction in coffee shop count from 85 to 70 raises questions about long-term volume stability.
• Trim Market: Spot trim pricing in Canada bottomed in Q3 at ~75% below year-ago levels, with expectations for normalization in Q4 due to new supply agreements and demand rebalancing.

Risks and Challenges:

• Spot Market Volatility: Significant price compression in Canadian trim and bulk flower volumes impacted Q3 margins.
• Regulatory Uncertainty: Pending federal hemp bans in the U.S. and evolving German/UK GMP regulations create supply chain complexities.
• Supply Constraints: International growth is currently capped by production capacity, though this is expected to ease with Delta II and Cronogen expansions.
• Seasonality: Predictable Q4 revenue dips in produce and international medical shipments.
• Illicit Market: Continued illicit trade in Canada and U.S. state-level regulatory restrictions impact potential volumes.

Management Commentary and Tone:

• Tone is confident and optimistic, particularly regarding the "greenwashing" crackdown in Europe and the regulatory shift in Texas.
• Management emphasized discipline on M&A, stating they will only pursue deals that are strategically compelling and accretive.
• Hamid Chikachi, the new Interim CFO, was welcomed for his 18 years of cannabis financial experience; Stephen Ruffini is transitioning to lead M&A efforts.
• Executives highlighted that price reductions in international markets were not observed; ASP declines were attributed to product mix shifts to bulk flour.
• Strong confidence expressed in the long-term value creation of the Delta II facility and the potential for U.S. interstate commerce and federal rescheduling.

Analyst Questions and Answers:

• EU GMP Pricing: Confirmed no price cuts on EU GMP product; regulators in UK and Germany are tightening rules, which should tighten the supply of compliant product and support Village Farms' pricing power.
• Capacity Allocation: Initial harvest from Delta II will be split between domestic Canada and international markets; Canada remains a strategic priority for long-term share gains.
• Delta 1 Conversion: Converting 25% of Delta 1 could add ~50-60 metric tons of capacity by 2028, running parallel processing certification to construction.
• Trim Pricing: Pricing for trim fell away in demand in Q3 but has not dropped further since then; normalization expected as large producer inventory dissipates.
• U.S. Entry Strategy: Village Farms plans to enter Texas "one way or another," potentially via the TCUP program or legislative changes; the Monahans facility is ready for conversion within 12 months.
• Customer Concentration: International business involves multiple customers, though specific counts are undisclosed; capacity constraints currently limit entry into new European countries.
• Netherlands Dynamics: Price compression is noted for competitors without GMP certification; Village Farms' ability to deliver consistent, pharmaceutical-grade volume is a key moat despite coffee shop count reductions.

Other Key Points:

• Delta 1 greenhouse conversion rights were formally exercised in mid-October with Vindexter (Verdexa) Holdings.
• Year-to-date cannabis sales grew double digits, and the company has delivered six consecutive quarters of positive net income.
• The company views itself as one of the world's largest and lowest-cost producers of high-quality cannabis, leveraging scale and controlled environment agriculture.
• Management highlighted the strategic advantage of Texas's low latitude, allowing for cannabis production in winter without supplemental lighting, offering a cost advantage over other regions.